NewAmsterdam Pharma N.V. (NAMS) vs Nurix Therapeutics (NRIX)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
Nurix Therapeutics (NRIX) has outperformed NewAmsterdam Pharma N.V. (NAMS) over the past year, gaining 122.5% versus a loss of 35.3%. Over five years, NAMS leads with a +117.2% price change compared with -23.0% for NRIX. NewAmsterdam Pharma N.V. is the larger company by market cap ($2.53 billion vs $2.39 billion), about 1.1 times the size, while Nurix Therapeutics is growing revenue faster (+54.0% vs -50.6%).
Nurix Therapeutics converts more of its revenue into profit, with a net margin of -314.9% versus -905.7%.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | NAMS | NRIX |
|---|---|---|
| Share price | $21.62 | $23.04 |
| Market cap | $2.53B | $2.39B |
| 1-day change | +1.69% | +3.74% |
| YTD return | -39.40% | +17.08% |
| 1-year return | -35.30% | +122.55% |
| 5-year return | +117.16% | -22.96% |
| EPS (TTM) | $-2.16 | $-3.46 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $22.50M | $83.98M |
| Revenue growth (YoY) | -50.61% | +53.95% |
| Net income (latest FY) | $-203.82M | $-264.46M |
| Operating margin | -1002.90% | -340.16% |
| Net margin | -905.74% | -314.90% |
| 52-week high | $42.21 | $28.23 |
| 52-week low | $20.91 | $9.00 |
| Distance from 52-week high | -48.77% | -18.38% |
| Analyst consensus | strong_buy | none |
| Avg. price target upside | +129.65% | +47.27% |
| Average volume | 1.36M | 1.28M |
| Shares outstanding | 116.90M | 103.78M |
| Employees | 100 | 317 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- NRIX has outperformed NAMS by 157.8 percentage points over the past year.
- Nurix Therapeutics is more profitable, keeping -314.9 cents of every revenue dollar as net income versus -905.7 cents for NewAmsterdam Pharma N.V..
- Nurix Therapeutics grew revenue faster in its latest fiscal year (+53.95% vs -50.61%).
About NewAmsterdam Pharma N.V.
NAMS stock →NewAmsterdam Pharma Company N.V., a late-stage biopharmaceutical company, develops therapies to enhance patient care in populations with cardiometabolic disease. It is developing Obicetrapib, an oral low-dose cholesteryl ester transfer protein (CETP) inhibitor, that is in various clinical trials as a monotherapy and a combination therapy with ezetimibe for lowering LDL-C for cardiovascular diseases.
Health Care · Biotechnology: Pharmaceutical Preparations · 100 employees
About Nurix Therapeutics
NRIX stock →Nurix Therapeutics, Inc., a clinical stage biopharmaceutical company, focuses on the discovery, development, and commercialization of small molecule and antibody therapies for the treatment of cancer, inflammatory conditions, and other diseases. The company develops NX-5948, an orally bioavailable BTK degrader, that is in Phase 2 clinical trials for the treatment of relapsed or refractory B-cell malignancies and autoimmune diseases; NX-2127, an orally bioavailable Bruton's tyrosine kinase (BTK) degrader, that is in Phase Phase 1a/1b clinical trials for the treatment of relapsed or refractory B-cell malignancies; and NX-1607, an orally bioavailable Casitas B-lineage lymphoma proto-oncogene-B (CBL-B) inhibitor, that is in Phase 1a/1b clinical trials to treat immuno-oncology indications.
Health Care · Biotechnology: Pharmaceutical Preparations · 317 employees
NAMS vs NRIX FAQ
Which is bigger, NewAmsterdam Pharma N.V. or Nurix Therapeutics?
NewAmsterdam Pharma N.V. (NAMS) is larger, with a market capitalization of $2.53B compared with $2.39B for Nurix Therapeutics (NRIX).
Which stock has performed better over the past year, NAMS or NRIX?
NRIX returned +122.55% over the past 12 months, compared with -35.30% for NAMS (price return, excluding dividends). Past performance does not predict future results.
Are NewAmsterdam Pharma N.V. and Nurix Therapeutics in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.